Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ551,5552,50,09
KB915,5916-0,27
PKN81,481,5-0,63
Msft99,65100,25-1,15
Nokia5,1165,12-0,51
IBM142,5142,99-1,00
DCX60,6460,66-1,75
PFE35,6136,20,46
19.6.2018 12:44:59
Indexy online
AD Index online
select
AD Index online
 

  • 18.6.2018
Kindred Biosciences (NASDAQ Cons)
Závěr k 18.6.2018 Změna (%) Změna (USD) Objem obchodů (ks)
10,50 -5,41 -0,60 117 142
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 19.6.2018
Popis společnosti
Obecné informace
Název společnostiKindred Biosciences Inc
TickerKIN
Kmenové akcie:Ordinary Shares
RICKIN.O
ISINUS4945771099
Poslední známé roční výsledky31.12.2017
Poslední známé čtvrtletní výsledky31.3.2018
Počet zaměstnanců k 31.12.2017 63
Akcie v oběhu k 4.5.2018 28 203 060
Počet akcionářů k 31.12.2017 24
MěnaUSD
Kontaktní informace
Ulice1555 Bayshore Hwy Ste 200
MěstoBURLINGAME
PSČ94010-1617
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 507 017 901
Fax13026451280

Business Summary: Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
Financial Summary: BRIEF: For the three months ended 31 March 2018, Kindred Biosciences Inc revenues was not reported. Net loss increased 54% to $10M. Higher net loss reflects General and administrative -Gross increase of 93% to $3.9M (expense), Research and development - Gross increase of 44% to $4.8M (expense), Stock Based Compensation in General and increase of 23% to $1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.30 to -$0.36.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 19.6.2018
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorRichard Chin5028.7.2018
Chief Financial OfficerWendy Wee6428.7.201728.7.2017
Chief Operating Officer, SecretaryDenise Bevers4711.11.2013
Chief Scientific OfficerHangjun Zhan-